Jun Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jun Liu has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
Suhayla Sarhan
4 shared publications- Claire Shao
Department of Pathology Brigham and Women's Hospital Boston Massachusetts USA
3 shared publications Kristine Geary
Department of Pathology Brigham and Women's Hospital Boston Massachusetts USA
3 shared publications- Li Chai
Department of Pathology, Brigham and Women’s Hospital, Boston, USA
3 shared publications Nelya Christiansen
3 shared publications- Hirotomo Nakahara
Department of Pathology Mass General Brigham Boston Massachusetts USA
2 shared publications
Latest Publications
- 11 July 2026
- Published by Wiley in Transfusion
Comparative analysis of motixafortide versus plerixafor for stem cell mobilization and collection in multiple myeloma: A single center real‐world experience
Background: Stem cell collection for autologous stem cell transplant after induction therapy remains standard for multiple myeloma (MM). Motixafortide, a novel C‐X‐C motif chemokine receptor 4 (CXCR4) antagonist with prolonged receptor occupancy compared to plerixafor, potentially enhances stem cell mobilization. Direct comparison with plerixafor in MM has not been reported. This quality initiative compares motixafortide + granulocyte colony‐stimulating factor (G‐CSF) versus plerixafor + G‐CSF for stem cell mobilization in MM patients at a single center, assessing feasibility, collection/mobilization outcomes, and safety. Study Design and Methods: A prospective cohort of 30 MM patients receiving motixafortide + G‐CSF was compared to a contemporary, retrospective cohort of covariate‐matched 30 patients receiving plerixafor + G‐CSF. Institutional apheresis procedure practices were followed. Primary outcomes included number of collection days, apheresis procedure duration, and adverse events requiring intervention. Results: Twenty‐nine of 30 motixafortide patients completed mobilization. CD34+ stem cell yields and apheresis procedure times were similar between groups; 27 patients per group reached collection targets in 1 day. Motixafortide recipients experienced more frequent adverse reactions (ARs) than plerixafor recipients. Conclusions: In this first real‐world comparison, use of motixafortide was feasible but not superior to plerixafor for MM mobilization. Motixafortide was associated with substantially higher rates of injection‐site and systemic ARs requiring intervention and imposed additional workflow demands for premedication and post‐injection monitoring. Due to the non‐superiority of motixafortide, decreasing acquisition costs for plerixafor and motixafortide's higher resource utilization, our institution favors continuing plerixafor as the default for MM mobilization. We reserve motixafortide for select patients, with ongoing evaluation of poor mobilizers to clarify its role in collection and post‐transplant outcomes.
- 11 July 2026
- Published by Wiley in Transfusion
Comparative analysis of motixafortide versus plerixafor for stem cell mobilization and collection in multiple myeloma: A single center real‐world experience
Background: Stem cell collection for autologous stem cell transplant after induction therapy remains standard for multiple myeloma (MM). Motixafortide, a novel C‐X‐C motif chemokine receptor 4 (CXCR4) antagonist with prolonged receptor occupancy compared to plerixafor, potentially enhances stem cell mobilization. Direct comparison with plerixafor in MM has not been reported. This quality initiative compares motixafortide + granulocyte colony‐stimulating factor (G‐CSF) versus plerixafor + G‐CSF for stem cell mobilization in MM patients at a single center, assessing feasibility, collection/mobilization outcomes, and safety. Study Design and Methods: A prospective cohort of 30 MM patients receiving motixafortide + G‐CSF was compared to a contemporary, retrospective cohort of covariate‐matched 30 patients receiving plerixafor + G‐CSF. Institutional apheresis procedure practices were followed. Primary outcomes included number of collection days, apheresis procedure duration, and adverse events requiring intervention. Results: Twenty‐nine of 30 motixafortide patients completed mobilization. CD34+ stem cell yields and apheresis procedure times were similar between groups; 27 patients per group reached collection targets in 1 day. Motixafortide recipients experienced more frequent adverse reactions (ARs) than plerixafor recipients. Conclusions: In this first real‐world comparison, use of motixafortide was feasible but not superior to plerixafor for MM mobilization. Motixafortide was associated with substantially higher rates of injection‐site and systemic ARs requiring intervention and imposed additional workflow demands for premedication and post‐injection monitoring. Due to the non‐superiority of motixafortide, decreasing acquisition costs for plerixafor and motixafortide's higher resource utilization, our institution favors continuing plerixafor as the default for MM mobilization. We reserve motixafortide for select patients, with ongoing evaluation of poor mobilizers to clarify its role in collection and post‐transplant outcomes.
- 22 June 2026
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 41 (3) , e70147
Chronic Red Cell Exchange for the Management of Alpha Thalassemia Major Complicated by Iron Overload
Alpha thalassemia major is a severe hemoglobinopathy characterized by absent or markedly reduced alpha‐globin production, necessitating lifelong blood transfusions. Chronic simple transfusions can lead to significant iron overload, often requiring iron chelation therapy. However, some patients are unable to tolerate chelation or chelation is insufficient, highlighting the need for alternative strategies for managing iron overload. This study is one of the first to evaluate the feasibility, safety, and efficacy of red blood cell exchange (RBCX) as a therapeutic option for managing iron overload while improving hemoglobin function in an alpha thalassemia major patient with iron overload despite chelation therapy. RBCX therapy was performed approximately every 3 weeks over 1 year, with frequent adjustment of exchange parameters to meet pre‐transfusion target levels of functional hemoglobin. Serum ferritin levels, hemoglobin electrophoresis, and functional hemoglobin levels were tracked with each exchange transfusion. For each RBCX treatment, variant hemoglobins decreased by 3.8‐fold (from 19.9% to 8.9%) and functional hemoglobin levels increased approximately 3.0 g/dL. RBCX was well tolerated and associated with a marked reduction in systemic iron burden, with serum ferritin declining 7.4‐fold (86.4%) over 1 year of therapy, followed by a rise after cessation of RBCX. Cardiac iron remained within normal limits throughout the study period. In contrast, liver iron demonstrated a transient increase shortly after initiation of RBCX, but ultimately declined to levels below baseline after 1 year, even during a period in the absence of iron chelation. These findings suggest that RBCX exerts a meaningful effect on iron homeostasis and raises the possibility of a synergistic benefit when combined with iron chelation. This case highlights that RBCX is a viable therapeutic strategy to treat iron overload in patients with alpha thalassemia major.
- 22 June 2026
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 41 (3) , e70147
Chronic Red Cell Exchange for the Management of Alpha Thalassemia Major Complicated by Iron Overload
Alpha thalassemia major is a severe hemoglobinopathy characterized by absent or markedly reduced alpha‐globin production, necessitating lifelong blood transfusions. Chronic simple transfusions can lead to significant iron overload, often requiring iron chelation therapy. However, some patients are unable to tolerate chelation or chelation is insufficient, highlighting the need for alternative strategies for managing iron overload. This study is one of the first to evaluate the feasibility, safety, and efficacy of red blood cell exchange (RBCX) as a therapeutic option for managing iron overload while improving hemoglobin function in an alpha thalassemia major patient with iron overload despite chelation therapy. RBCX therapy was performed approximately every 3 weeks over 1 year, with frequent adjustment of exchange parameters to meet pre‐transfusion target levels of functional hemoglobin. Serum ferritin levels, hemoglobin electrophoresis, and functional hemoglobin levels were tracked with each exchange transfusion. For each RBCX treatment, variant hemoglobins decreased by 3.8‐fold (from 19.9% to 8.9%) and functional hemoglobin levels increased approximately 3.0 g/dL. RBCX was well tolerated and associated with a marked reduction in systemic iron burden, with serum ferritin declining 7.4‐fold (86.4%) over 1 year of therapy, followed by a rise after cessation of RBCX. Cardiac iron remained within normal limits throughout the study period. In contrast, liver iron demonstrated a transient increase shortly after initiation of RBCX, but ultimately declined to levels below baseline after 1 year, even during a period in the absence of iron chelation. These findings suggest that RBCX exerts a meaningful effect on iron homeostasis and raises the possibility of a synergistic benefit when combined with iron chelation. This case highlights that RBCX is a viable therapeutic strategy to treat iron overload in patients with alpha thalassemia major.
- 11 December 2025
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 40 (6) , e70080
A Web‐Based Calculator for Hematopoietic Progenitor Cell Collections: App Development and Retrospective Assessment
A major challenge in hematopoietic progenitor cell apheresis is determining the whole blood (WB) volume to process to achieve a CD34+ cell collection goal. We developed a web‐based calculator app that uses the Collection Efficiency 2 (CE2) model to estimate personalized WB processing volumes needed to reach a prescribed CD34+ cell collection goal. Retrospective evaluation of the app using collection data from two academic medical centers showed that actual processed WB volumes were frequently higher than the app's recommendations. The frequency of potential under‐collection events is predicted to be low had the app‐calculated volumes been utilized. Our findings suggest that using the app's recommendations may lower total WB processing volumes, reducing over‐collection and time spent on the apheresis machine, while maintaining a low under‐collection risk profile.
- 11 December 2025
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 40 (6) , e70080
A Web‐Based Calculator for Hematopoietic Progenitor Cell Collections: App Development and Retrospective Assessment
A major challenge in hematopoietic progenitor cell apheresis is determining the whole blood (WB) volume to process to achieve a CD34+ cell collection goal. We developed a web‐based calculator app that uses the Collection Efficiency 2 (CE2) model to estimate personalized WB processing volumes needed to reach a prescribed CD34+ cell collection goal. Retrospective evaluation of the app using collection data from two academic medical centers showed that actual processed WB volumes were frequently higher than the app's recommendations. The frequency of potential under‐collection events is predicted to be low had the app‐calculated volumes been utilized. Our findings suggest that using the app's recommendations may lower total WB processing volumes, reducing over‐collection and time spent on the apheresis machine, while maintaining a low under‐collection risk profile.
- 18 November 2025
- Published by Wiley in Transfusion
- Vol. 66 (1) , 197-204
Feasibility and utility of a rapid ABO genotyping platform in transplantation and transfusion medicine
Background: Serological ABO typing in transfusion medicine and organ transplantation, can face limitations in cases involving large volume transfusions, transplants, weak subgroups, or hematological malignancies. ABO genotyping can help resolve ABO type, and there is a need for a fast, reliable, and cost‐effective testing approach. Study Design and Methods: We investigate a commercially available medium‐throughput quantitative polymerase chain reaction (qPCR) ABO genotyping assay and evaluated routine samples from a tertiary academic transplant laboratory, samples previously ABO genotyped in the immunohematology and genomics reference laboratory, and samples showing discordant/mixed field reactivity in the hospital blood bank. Results were compared with serologic typing and Sanger sequencing, or next‐generation sequencing (NGS) for some. Results: For routine transplant samples ( n = 89), the qPCR assay demonstrated 100% concordance with serologic phenotypes and Sanger sequencing with one no‐call result. For complex reference laboratory samples ( n = 32), 91% concordance with serologic phenotype and 72% concordance with predicted phenotype and genotype by Sanger sequencing was achieved. qPCR identified variants encoding: A 1 , A 2 , A 3 , and cisAB. In blood bank problem samples ( n = 29), 79% were resolved by qPCR. Discussion: The qPCR assay's rapid turnaround time and automated interpretation make it particularly suitable for inclusion in the investigation and resolution of ABO serological typing problems. Its capabilities also align well with recent UNOS (United Network for Organ Sharing) guidance for deceased kidney donor ABO typing resolution and can potentially improve patient safety in transplantation settings, and aid in the evaluation of typing discrepancies in transfusion medicine practice.
- 18 November 2025
- Published by Wiley in Transfusion
- Vol. 66 (1) , 197-204
Feasibility and utility of a rapid ABO genotyping platform in transplantation and transfusion medicine
Background: Serological ABO typing in transfusion medicine and organ transplantation, can face limitations in cases involving large volume transfusions, transplants, weak subgroups, or hematological malignancies. ABO genotyping can help resolve ABO type, and there is a need for a fast, reliable, and cost‐effective testing approach. Study Design and Methods: We investigate a commercially available medium‐throughput quantitative polymerase chain reaction (qPCR) ABO genotyping assay and evaluated routine samples from a tertiary academic transplant laboratory, samples previously ABO genotyped in the immunohematology and genomics reference laboratory, and samples showing discordant/mixed field reactivity in the hospital blood bank. Results were compared with serologic typing and Sanger sequencing, or next‐generation sequencing (NGS) for some. Results: For routine transplant samples ( n = 89), the qPCR assay demonstrated 100% concordance with serologic phenotypes and Sanger sequencing with one no‐call result. For complex reference laboratory samples ( n = 32), 91% concordance with serologic phenotype and 72% concordance with predicted phenotype and genotype by Sanger sequencing was achieved. qPCR identified variants encoding: A 1 , A 2 , A 3 , and cisAB. In blood bank problem samples ( n = 29), 79% were resolved by qPCR. Discussion: The qPCR assay's rapid turnaround time and automated interpretation make it particularly suitable for inclusion in the investigation and resolution of ABO serological typing problems. Its capabilities also align well with recent UNOS (United Network for Organ Sharing) guidance for deceased kidney donor ABO typing resolution and can potentially improve patient safety in transplantation settings, and aid in the evaluation of typing discrepancies in transfusion medicine practice.
- Open Access
Dissecting the cell of origin of aberrant SALL4 expression in myelodysplastic syndrome
Myelodysplastic syndrome (MDS) is a group of heterogeneous diseases characterized by cytologic dysplasia and cytopenias resulting from ineffective hematopoiesis. Oncofetal protein SALL4 is a known oncogene in MDS and its baseline expression level serves as a prognostic biomarker for MDS at the time of diagnosis. In addition, a recent study showed that SALL4 upregulation following hypomethylating agent treatment in MDS patients correlates with poor outcomes. Despite its important mechanistic and diagnostic significance, the cellular identity of bone marrow cells with aberrant SALL4 expression in MDS patients remains unknown. In this study, we analyzed MDS bone marrow cells on single cell level by mass cytometry (CyTOF) and found that SALL4 was mainly aberrantly expressed in the hematopoietic stem and progenitor cells (HSPC) as well as myeloid lineages. Within the HSPC population from MDS patients, SALL4 and p53 were co-expressed, with the highest co-expressing clones harboring pathogenic TP53 mutations. Overall, our study characterizes for the first time the aberrant SALL4 expression in primary MDS patient samples at a single-cell level. Further studies on the SALL4/p53 network for in-depth mechanistic investigation are needed in the future. Key Points SALL4 expression in various MDS BM cells confirmed by mass cytometry (CyTOF). SALL4 and p53 double positive cells were predominantly found in the hematopoietic stem and progenitor cell (HSPC) population and associated with pathogenic TP53 mutation status.
Open AccessDissecting the cell of origin of aberrant SALL4 expression in myelodysplastic syndrome
Myelodysplastic syndrome (MDS) is a group of heterogeneous diseases characterized by cytologic dysplasia and cytopenias resulting from ineffective hematopoiesis. Oncofetal protein SALL4 is a known oncogene in MDS and its baseline expression level serves as a prognostic biomarker for MDS at the time of diagnosis. In addition, a recent study showed that SALL4 upregulation following hypomethylating agent treatment in MDS patients correlates with poor outcomes. Despite its important mechanistic and diagnostic significance, the cellular identity of bone marrow cells with aberrant SALL4 expression in MDS patients remains unknown. In this study, we analyzed MDS bone marrow cells on single cell level by mass cytometry (CyTOF) and found that SALL4 was mainly aberrantly expressed in the hematopoietic stem and progenitor cells (HSPC) as well as myeloid lineages. Within the HSPC population from MDS patients, SALL4 and p53 were co-expressed, with the highest co-expressing clones harboring pathogenic TP53 mutations. Overall, our study characterizes for the first time the aberrant SALL4 expression in primary MDS patient samples at a single-cell level. Further studies on the SALL4/p53 network for in-depth mechanistic investigation are needed in the future. Key Points SALL4 expression in various MDS BM cells confirmed by mass cytometry (CyTOF). SALL4 and p53 double positive cells were predominantly found in the hematopoietic stem and progenitor cell (HSPC) population and associated with pathogenic TP53 mutation status.
- Open Access
- 1 July 2020
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 13, 2417-2423
Disk-Diffusion Testing Is an Inappropriate Screening Tool for Cephalosporin-Resistant Gonorrhoea Strains in Clinical Practice in China
Purpose: Injectable ceftriaxone and oral cefixime are the last agents effective against Neisseria gonorrhoeae. In vitro antimicrobial-susceptibility testing (AST) is done to identify the most efficacious antibiotic needed to combat the infection in that particular individual. The objective of this study was to evaluate whether Kirby–Bauer (KB) disk-diffusion tests can detect N. gonorrhoeae isolates that have decreased susceptibility to ceftriaxone and cefixime for appropriate clinical management. Methods: A total of 1,633 consecutive clinical isolates of N. gonorrhoeae were collected from January 1, 2013 to December 31, 2017 from seven dermatology clinics located in five provinces in China. Consistency between KB disk-diffusion tests and the agar-dilution method, as well as sensitivity of the KB test for detecting N. gonorrhoeae isolates with decreased susceptibility to ceftriaxone and cefixime, were determined using 1,306 clinical isolates that had been recovered to complete agar-dilution AST. Results: The prevalence of isolates with decreased susceptibility to ceftriaxone and cefixime was 12.1% (198 of 1,633) and 12.7% (208 of 1,633), respectively, using KB disk-diffusion tests. The prevalence of isolates with decreased susceptibility was 9.9% (129 of 1,306) for ceftriaxone and 9.9% (129 of 1,305) for cefixime using agar-dilution AST. The categorical agreement of these two methods was 80.9% for both ceftriaxone and cefixime. Compared to agar-dilution AST, the sensitivity of the KB test for detecting N. gonorrhoeae isolates with decreased susceptibility was 22.5% (29 of 129) for ceftriaxone and 29.5% (38 of 129) for cefixime, and its specificity 87.3% (1,028 of 1,177) for ceftriaxone and 86.7% (1,018 of 1,176) for cefixime. Conclusion: Although KB tests are easy to carry out in clinical practice, their ability to detect cephalosporin-resistant gonorrhoea strains is limited. This method is not an appropriate selection for screening cephalosporin-resistant gonorrhoea strains in clinical practice in China.
- 1 July 2020
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 13, 2417-2423
Open AccessDisk-Diffusion Testing Is an Inappropriate Screening Tool for Cephalosporin-Resistant Gonorrhoea Strains in Clinical Practice in China
Purpose: Injectable ceftriaxone and oral cefixime are the last agents effective against Neisseria gonorrhoeae. In vitro antimicrobial-susceptibility testing (AST) is done to identify the most efficacious antibiotic needed to combat the infection in that particular individual. The objective of this study was to evaluate whether Kirby–Bauer (KB) disk-diffusion tests can detect N. gonorrhoeae isolates that have decreased susceptibility to ceftriaxone and cefixime for appropriate clinical management. Methods: A total of 1,633 consecutive clinical isolates of N. gonorrhoeae were collected from January 1, 2013 to December 31, 2017 from seven dermatology clinics located in five provinces in China. Consistency between KB disk-diffusion tests and the agar-dilution method, as well as sensitivity of the KB test for detecting N. gonorrhoeae isolates with decreased susceptibility to ceftriaxone and cefixime, were determined using 1,306 clinical isolates that had been recovered to complete agar-dilution AST. Results: The prevalence of isolates with decreased susceptibility to ceftriaxone and cefixime was 12.1% (198 of 1,633) and 12.7% (208 of 1,633), respectively, using KB disk-diffusion tests. The prevalence of isolates with decreased susceptibility was 9.9% (129 of 1,306) for ceftriaxone and 9.9% (129 of 1,305) for cefixime using agar-dilution AST. The categorical agreement of these two methods was 80.9% for both ceftriaxone and cefixime. Compared to agar-dilution AST, the sensitivity of the KB test for detecting N. gonorrhoeae isolates with decreased susceptibility was 22.5% (29 of 129) for ceftriaxone and 29.5% (38 of 129) for cefixime, and its specificity 87.3% (1,028 of 1,177) for ceftriaxone and 86.7% (1,018 of 1,176) for cefixime. Conclusion: Although KB tests are easy to carry out in clinical practice, their ability to detect cephalosporin-resistant gonorrhoea strains is limited. This method is not an appropriate selection for screening cephalosporin-resistant gonorrhoea strains in clinical practice in China.
- Open Access
- 1 August 2019
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 12, 2471-2476
Gentamicin susceptibility of Neisseria gonorrhoeae isolates from 7 provinces in China
Purpose: Gentamicin is a promising antimicrobial for the treatment of gonorrhea. The study aimed to evaluate gentamicin minimum inhibitory concentrations (MICs) of Neisseria gonorrhoeae isolates in China. Methods: In this study, the agar dilution method was used to determine the MICs of 470 isolates collected in 2016 to four effective antimicrobials (gentamicin, azithromycin, ceftriaxone, and spectinomycin). Results: Gentamicin MICs ranged from 1 to 8 mg/L. No isolate was resistant to gentamicin. Of seven isolates simultaneously resistant to azithromycin and ceftriaxone, 6 isolates demonstrated MICs of 4 mg/L or less to gentamicin. No cross relationships were found between MICs of gentamicinand susceptibility profiles of azithromycin, ceftriaxone, and spectinomycin. Conclusion: The in vitro results suggest that gentamicin can be a promising treatment option for gonococcal infections in China. Clinical trials to evaluate the therapeutic efficacy of gentamicin are required.
- 1 August 2019
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 12, 2471-2476
Open AccessGentamicin susceptibility of Neisseria gonorrhoeae isolates from 7 provinces in China
Purpose: Gentamicin is a promising antimicrobial for the treatment of gonorrhea. The study aimed to evaluate gentamicin minimum inhibitory concentrations (MICs) of Neisseria gonorrhoeae isolates in China. Methods: In this study, the agar dilution method was used to determine the MICs of 470 isolates collected in 2016 to four effective antimicrobials (gentamicin, azithromycin, ceftriaxone, and spectinomycin). Results: Gentamicin MICs ranged from 1 to 8 mg/L. No isolate was resistant to gentamicin. Of seven isolates simultaneously resistant to azithromycin and ceftriaxone, 6 isolates demonstrated MICs of 4 mg/L or less to gentamicin. No cross relationships were found between MICs of gentamicinand susceptibility profiles of azithromycin, ceftriaxone, and spectinomycin. Conclusion: The in vitro results suggest that gentamicin can be a promising treatment option for gonococcal infections in China. Clinical trials to evaluate the therapeutic efficacy of gentamicin are required.